Thromboembolism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Thromboembolism - Pipeline Review, H2 2016

Thromboembolism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Thromboembolism - Pipeline Review, H2 2016
Published Jul 20, 2016
101 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Thromboembolism - Pipeline Review, H2 2016, provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thromboembolism
- The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects
- The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thromboembolism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8289IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Thromboembolism Overview81
Therapeutics Development92
  Pipeline Products for Thromboembolism Overview91
  Pipeline Products for Thromboembolism Comparative Analysis101
Thromboembolism Therapeutics under Development by Companies111
Thromboembolism Therapeutics under Investigation by Universities/Institutes121
Thromboembolism Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Thromboembolism Products under Development by Companies161
Thromboembolism Products under Investigation by Universities/Institutes171
Thromboembolism Companies Involved in Therapeutics Development1811
  Bayer AG181
  Cereno Scientific AB191
  China Biologic Products, Inc.201
  Daiichi Sankyo Company, Limited211
  F. Hoffmann-La Roche Ltd.221
  Gamma Therapeutics, Inc.231
  GlycoMimetics, Inc.241
  Green Cross Corporation251
  Ionis Pharmaceuticals, Inc.261
  Portola Pharmaceuticals, Inc.271
  The International Biotechnology Center (IBC) Generium281
Thromboembolism Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3842
  alteplase biosimilar Drug Profile381
  antithrombin III (human) Drug Profile391
  betrixaban Drug Profile404
  C-3 Drug Profile441
  CS-1 Drug Profile451
  edoxaban tosylate Drug Profile465
  Gammarin Drug Profile511
  GCC-2107 Drug Profile521
  GMI-1271 Drug Profile535
  IONIS-FXIRx Drug Profile583
  Lysimab Drug Profile611
  Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism Drug Profile621
  Recombinant Protein for Thromboembolism Drug Profile631
  rivaroxaban Drug Profile6413
  TAP-ANV Drug Profile771
  TRX-1 Drug Profile781
  YG-001 Drug Profile791
Thromboembolism Dormant Projects801
Thromboembolism Discontinued Products811
Thromboembolism Product Development Milestones8218
  Featured News &Press Releases821
    May 27, 2016: Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting821
    May 23, 2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on Betrixaban at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting831
    Apr 06, 2016: Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis SSC Meeting 2016 on May 27, 2016831
    Mar 30, 2016: Bristol-Myers Squibb And Pfizer Announce Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology S 65Th Annual Scientific Session844
    Mar 24, 2016: Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients881
    Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer892
    Nov 30, 2015: New Data from Bayer s Portfolio in Thrombosis to be Presented at ASH 2015911
    Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015913
    Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients941
    Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis951
    Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients961
    Sep 24, 2015: Bayer s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis961
    Sep 24, 2015: Bayer s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis971
    Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots971
    Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer982
Appendix1002
  Methodology1001
  Coverage1001
  Secondary Research1001
  Primary Research1001
  Expert Panel Validation1001
  Contact Us1001
  Disclaimer1011

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Thromboembolism - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Thromboembolism-Pipeline-Review-H2-2016-2088-16252>
  
APA:
Global Markets Direct - Market Research. (2016). Thromboembolism - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Thromboembolism-Pipeline-Review-H2-2016-2088-16252>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.